Stock AnalizSTERIS (STE) earnings for the quarter ended September 2026: EPS beats estimates
STERIS reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at $2.94 against the analysts’ average forecast of $2.68, a beat of 9.8%.
Revenue for the quarter was $1.59 billion, up 8.8% from $1.46 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 9.8% on the first trading day after the report.
The last four quarters
STERIS has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.94 | $2.68 | +9.8% | +9% | +9.8% |
| Jun 2026 | $2.59 | $2.49 | +3.9% | +7% | −0.5% |
| Mar 2026 | $2.83 | $2.85 | −0.7% | +7% | +1.6% |
| Dec 2025 | $2.53 | $2.53 | −0.1% | +9% | −6.8% |
What comes next
Analysts expect EPS of $2.79 for the next quarter on average and $11.44 for the fiscal year ending March 31, 2027.
The average analyst price target is $281.14, 6% above the current price of $264.32.
Valuation and score
STERIS scores 3.0 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 31.4, and its intrinsic value under moderate assumptions is about 43% below the current market value. Full STERIS analysis with 10 years of financials
Frequently asked questions
What was STERIS’s EPS for the quarter ended September 2026?
$2.94 adjusted per share, against an analyst consensus of $2.68.
How much revenue did STERIS report?
$1.59 billion, up 8.8% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.